{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-044141","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2023-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.424593+00:00","generated_at":"2026-06-10T16:01:47.175427+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rocket Pharmaceuticals raises ~$188.9M in public offering of common stock and pre-funded warrants","bullets":["Offered 7,812,500 shares at $16.00/share and pre-funded warrants for 3,126,955 shares at $15.99 each.","Underwriters exercised full 30-day option to purchase an additional 1,640,918 shares.","Net proceeds of ~$188.9M to fund gene therapy pipeline including RP-A501 Phase 2 trial.","90-day lock-up agreements for executive officers, directors, and certain shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-044141","json":"https://secwatch.observer/filing/0001140361-23-044141.json","markdown":"https://secwatch.observer/filing/0001140361-23-044141.md","text":"https://secwatch.observer/filing/0001140361-23-044141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123044141/0001140361-23-044141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123044141/ny20010507x5_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T16:01:47.175427+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d68a6ea5375c824329aa2cc37e66f7d83e15e8a0","claim":"ROCKET PHARMACEUTICALS, INC. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Leerink Partners LLC and Cowen and Company, LLC (effective 2023-09-12).","evidence_excerpt":"On September 12, 2023, Rocket Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Leerink Partners LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule A thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to (i) 7,812,500 shares of common stock (the “Shares”), and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 3,126,955 shares of common stock (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123044141/0001140361-23-044141-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Leerink Partners LLC and Cowen and Company, LLC"},{"label":"Effective","value":"2023-09-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}